Peripheral Arterial Disease Clinical Trial
Official title:
A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR™ 018 Drug Eluting Balloon in the Treatment of Subjects With Femoropopliteal Artery Lesions
This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 1, 2029 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Clinical Inclusion Criteria: 1. Subject age is = 18 years or minimum legal age as required by local regulations. 2. Life expectancy >1 year in opinion of investigator. 3. Documented ischemia with Rutherford classification category 2, 3 or 4. 4. Target lesion(s) in the SFA or PPA. 5. Able to walk without the assistance of a walker. 6. Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations. 7. Female subjects only: If female, then subjects of childbearing potential must have a negative pregnancy test = 7 days before the procedure and be prepared to use effective contraception for 12 months after treatment. Angiographic Inclusion Criteria: 1. Angiographic evidence that target lesion lies within the superficial femoral artery and/or proximal popliteal artery (P1 and P2 only). 2. Angiographic evidence that the target lesion consists of either a de novo lesion or a non-stented restenotic lesion, or a combination of both, that meets one of the following criteria: A. A stenosis of 70-99% with lesion length between =3cm and <20cm by visual estimation. B. A total (100%) occlusion with lesion length between =3cm and =10cm by visual estimation. C. A combination lesion (stenosis and total occlusion) must have a total lesion length between =3cm and <20cm by visual estimation with an occluded segment that is =10cm by visual estimation. D. If multiple lesions are to be treated, then only 2 lesions may be included. The total combination of lengths must be between =3cm and < 20cm by visual estimation, and there must be at least 5 cm of artery that is not to be treated between them. 3. Target vessel reference diameter =4mm and =7mm. 4. Patent arterial inflow (common iliac, external iliac, common femoral and profunda femoris arteries, and the proximal 2 cm of the SFA) free from significant lesion (defined as =50% stenosis) as confirmed on angiography. Note: Where required, inflow iliac arteries (common and external iliac arteries only) must be successfully treated during the index procedure. Completion angiography must confirm successful treatment of inflow disease (=30% residual stenosis, no distal embolization, and no Grade C or greater dissection ) prior to pre-dilation and randomization of the target lesion(s). Drug-eluting devices are not allowed for treatment of the occluded inflow iliac arteries. 5. Angiographic evidence of adequate distal run off (defined as =50% stenosis) in one or more tibial arteries on initial angiography, and if applicable, after completion of inflow artery treatment. Note: Treatment of outflow disease is permitted during the index procedure. Drug-eluting devices are not allowed for outflow treatment. Clinical Exclusion Criteria: 1. Other surgical or endovascular procedure in the target limb that occurred within 14 days prior to index procedure or is planned for within 30 days following index procedure, with exception for diagnostic angiography. 2. Inability to tolerate dual antiplatelet therapy. 3. Known hypersensitivity or allergy to Sirolimus or other pharmacologic agents, such as contrast agent, which are required for the procedure and which cannot be adequately pre-treated. 4. Stroke or MI within 3 months of enrollment. 5. Symptom onset less than 14 days prior to index procedure (acute limb ischemia). 6. Lower limb disease in the contralateral leg that requires treatment at the index procedure, or, that is planned within 14 days prior to the index procedure or within 30 days after the index procedure. 7. Prior vascular surgery (including bypass and endarterectomy) of abdominal aorta, iliac arteries, or arteries of the index limb. 8. Non-atherosclerotic disease of the index limb (including aneurysmal disease, vasculitis, Buerger's disease) 9. Target lesion requires treatment with alternative therapies such as thrombolysis, thrombus aspiration, cutting/scoring/contoured balloon, stenting, laser, cryoplasty, intravascular lithotripsy, brachytherapy, re-entry device). 10. Subject has target lesion(s) that require treatment via pedal site. 11. Subject has target lesion(s) that require access via upper extremity arteries. 12. Hypercoagulable state or disorder present, or coagulopathy present, including platelet count less than 80,000 per microliter. 13. Chronic renal insufficiency (dialysis dependent, or serum creatinine >2.5 mg/dL within 30 days of index procedure). 14. Systemic infection (WBC > 12,000 and febrile) or known immune compromise. 15. Breast-feeding woman. 16. Currently participating in another investigational drug or device study that has not completed primary endpoint follow-up. Angiographic Exclusion Criteria: 1. Presence of a previously placed stent in the treated artery. 2. Failure to successfully cross the target lesion. 3. Residual stenosis =30% after pre-dilatation. |
Country | Name | City | State |
---|---|---|---|
Austria | Universitätsklinikum Graz | Graz | |
Germany | Universitäts-Herzzentrum Freiburg - Bad Krozingen | Bad Krozingen | |
Germany | Krankenhaus Buchholz | Buchholz | |
Germany | Universitätsklinikum Leipzig | Leipzig | |
Germany | RoMed Klinikum Rosenheim | Rosenheim | |
Germany | University Clinic Tübingen | Tübingen | |
Hong Kong | The Chinese University of Hong Kong | Sha Tin | |
United States | Emory University Hospital | Atlanta | Georgia |
United States | Manatee Memorial Hospital | Bradenton | Florida |
United States | James J. Peters VA Medical Center | Bronx | New York |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | OhioHealth Riverside Hospital | Columbus | Ohio |
United States | Vascular Care Group | Darien | Connecticut |
United States | Vascular Institute of the Midwest | Davenport | Iowa |
United States | Mission Cardiovascular Research Institute | Fremont | California |
United States | The Cardiac and Vascular Institute Research Foundation | Gainesville | Florida |
United States | Cardiovascular Institute of the South | Gray | Louisiana |
United States | Baylor College of Medicine | Houston | Texas |
United States | MedStar Health Research Institute | Hyattsville | Maryland |
United States | First Coast Cardiovascular Institute | Jacksonville | Florida |
United States | St. Bernards Medical Center | Jonesboro | Arkansas |
United States | Arkansas Heart Hospital | Little Rock | Arkansas |
United States | Palm Vascular Centers | Miami Beach | Florida |
United States | Yale University | New Haven | Connecticut |
United States | Mount Sinai | New York | New York |
United States | Advocate Lutheran General Hospital | Park Ridge | Illinois |
United States | Miriam Hospital | Providence | Rhode Island |
United States | NC Heart and Vascular Research, LLC | Raleigh | North Carolina |
United States | St. Helena Hospital | Saint Helena | California |
United States | Mercy Hospital | Saint Louis | Missouri |
United States | Texas Cardiac and Vascular Institute San Antonio | San Antonio | Texas |
United States | Holy Name Medical Center | Teaneck | New Jersey |
United States | Cardiovascular Consultants of South Georgia | Thomasville | Georgia |
United States | ClinRé | Thornton | Colorado |
United States | Tennessee Center for Clinical Trials | Tullahoma | Tennessee |
United States | Guardian Research Organization, LLC | Winter Park | Florida |
Lead Sponsor | Collaborator |
---|---|
MedAlliance, LLC | NAMSA |
United States, Austria, Germany, Hong Kong,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Efficacy Endpoint | Primary patency of the target lesion defined as freedom from ANY of the following adverse events:
Clinically driven target lesion revascularization (CD-TLR, defined as re-intervention of target lesion(s) due to recurrent, persistent, or worsening symptoms and angiographic restenosis (= 50% diameter stenosis) of target lesion by ACL measurement) OR Restenosis as determined by core lab adjudicated duplex ultrasound peak systolic velocity ratio of >2.4 or occlusion of the target lesion. |
12 months | |
Primary | Primary Safety Endpoint | The primary safety endpoint is the freedom from ANY of the following adverse events:
All-cause perioperative death (POD) [evaluated at 30 days] OR Target limb major (above-the-ankle) amputation [evaluated at 12 months] OR Clinically driven target lesion revascularization (CD-TLR) [evaluated at 12 months] |
30 days or 12 months | |
Secondary | Powered Secondary Endpoints | If both primary endpoints are met, the following endpoint will be tested for superiority in a sequential manner:
• Clinically driven target lesion revascularization (CD-TLR) |
12 months | |
Secondary | Device success | A secondary performance endpoint defined as successful delivery, balloon inflation, deflation, and retrieval of the intact investigational device. | Immediately following the procedure | |
Secondary | Procedural (technical) success | A secondary performance endpoint defined as device success and residual diameter stenosis = 30% on completion angiography by core lab assessment. | Immediately following the procedure | |
Secondary | Clinical success | A secondary performance endpoint defined as procedural success without procedural complications (death, above-ankle target limb amputation, thrombosis of the target lesion or TLR) prior to discharge. | Discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first | |
Secondary | Secondary Safety Endpoints | Major adverse limb events (MALE).
Major cardiovascular events, myocardial infarction (MI), and stroke. All-cause mortality. |
1, 6, and 12 months, and 2-5 years | |
Secondary | Primary sustained clinical improvement | A secondary efficacy endpoint defined as freedom from target limb major amputation and CD-TLR AND increase in Rutherford category from baseline. | 1, 6, and 12 months, and 2-5 years | |
Secondary | Secondary sustained clinical improvement | A secondary efficacy endpoint defined as freedom from target limb major amputation AND increase in Rutherford category from baseline.
Major amputation, defined as above-the-ankle amputation of the target limb. Amputation-free survival, defined as freedom from all-cause mortality and major amputation. |
1, 6, and 12 months, and 2-5 years | |
Secondary | Major amputation | A secondary efficacy endpoint defined as above-the-ankle amputation of the target limb. | 1, 6, and 12 months, and 2-5 years | |
Secondary | Amputation-free survival | A secondary efficacy endpoint defined as freedom from all-cause mortality and major amputation. | 1, 6, and 12 months, and 2-5 years | |
Secondary | Primary assisted patency | A secondary efficacy endpoint defined as freedom from target lesion occlusion by duplex ultrasound core laboratory [DCL] adjudication), irrespective of interventions for stenoses. | 12 and 24 months | |
Secondary | Secondary patency | A secondary efficacy endpoint defined as freedom from permanent occlusion (occlusion at the last follow-up imaging) as determined by the DCL.
Freedom from CD-TLR and binary restenosis as determined by the DCL [at 1, 3, 6, 12, 24, 36 months]. Any TLR, defined as any re-intervention of target lesion(s) 1, 6, and 12 months, and 2-5 years |
12 and 24 months | |
Secondary | Freedom from CD-TLR and binary restenosis | A secondary efficacy endpoint defined as freedom from Clinically driven target lesion revascularization and binary restenosis as determined by the duplex ultrasound core laboratory (DCL). | 1, 3, 6, 12, 24, 36 months | |
Secondary | Any TLR | A secondary efficacy endpoint defined as any re-intervention of target lesion(s). | 1, 6, and 12 months, and 2-5 years | |
Secondary | CD-TLR | A secondary efficacy endpoint defined as re-intervention of target lesion(s) due to recurrent/persistent/worsening symptoms and the angiographic finding of = 50% restenosis of target lesion by ACL measurement. | 1, 6, and 12 months, and 2-5 years | |
Secondary | Clinically driven Target Vessel Revascularization (TVR) | A secondary efficacy endpoint defined as re-intervention of target vessel due to recurrent/persistent/worsening symptoms and the angiographic finding of = 50% restenosis of target vessel by ACL measurement. | 1, 6, and 12 months, and 2-5 years | |
Secondary | Target lesion thrombosis | A secondary efficacy endpoint assessed by angiographic or DUS core laboratory adjudication. | 1, 6, and 12 months, and 2-5 years | |
Secondary | Rutherford category | A secondary efficacy endpoint defined as change in Rutherford category from baseline. | 1, 6, 12, 24 and 36 months | |
Secondary | Ankle brachial index (ABI) | A secondary efficacy endpoint defined as change in ankle brachial index (ABI) from baseline. | 12 and 24 months | |
Secondary | Walking capacity | A secondary efficacy endpoint defined as change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ) from baseline. | 1, 6, 12, 24 and 36 months | |
Secondary | Secondary Imaging endpoints (DCL adjudicated): | Primary duplex-defined binary restenosis - Peak Systolic Velocity Ratio (PSVR)>2.4.
Alternate duplex-defined binary restenosis - Peak Systolic Velocity Ratio (PSVR)>3.4. |
12 and 24 months | |
Secondary | Secondary Quality of life and health economic assessments (1) | • Change in EQ-5D score from baseline. OBS.: Following EuroQol terminology: Scores are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead. | 12 months | |
Secondary | Secondary Quality of life and health economic assessments (2) | • Days of target lesion-related hospitalization at 12 months. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |